[go: up one dir, main page]

UA83738C2 - [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase - Google Patents

[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase

Info

Publication number
UA83738C2
UA83738C2 UAA200611261A UAA200611261A UA83738C2 UA 83738 C2 UA83738 C2 UA 83738C2 UA A200611261 A UAA200611261 A UA A200611261A UA A200611261 A UAA200611261 A UA A200611261A UA 83738 C2 UA83738 C2 UA 83738C2
Authority
UA
Ukraine
Prior art keywords
compound
inhibitor
formula
present
thiophen
Prior art date
Application number
UAA200611261A
Other languages
English (en)
Ukrainian (uk)
Inventor
Чжунли Гао
Ларри Девис
Джулиан Левелл
Марк Чекай
Адам В. Следески
Эль-Бдауи Аддад
Original Assignee
Авентис Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авентис Фармасьютикалз Инк. filed Critical Авентис Фармасьютикалз Инк.
Publication of UA83738C2 publication Critical patent/UA83738C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Данное изобретение относится к соединению формулы І:(I)или пролекарств, фармацевтически приемлемой соли или сольвата указанного соединения.Кроме того, данное изобретение относится к фармацевтической композиции, которая содержит фармацевтически эффективное количество соединения формулы І и фармацевтически приемлемый носитель.Кроме того, данное изобретение относится к применению соединения формулы І как ингибитора триптазы, что предусматривает введение соединения в состав, который включает триптазу.Данное изобретение также относится к применению соединения формулы І для лечения пациентов, страдающих или предрасположенных к физиологическим заболеваниям, при которых необходимо повышение уровня ингибитора триптазы, при этом такое лечение предусматривает введение пациенту терапевтически эффективного количест�
UAA200611261A 2004-03-26 2005-03-24 [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase UA83738C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55692704P 2004-03-26 2004-03-26
PCT/US2005/009899 WO2005097780A1 (en) 2004-03-26 2005-03-24 [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase

Publications (1)

Publication Number Publication Date
UA83738C2 true UA83738C2 (en) 2008-08-11

Family

ID=34964263

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200611261A UA83738C2 (en) 2004-03-26 2005-03-24 [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase

Country Status (25)

Country Link
US (1) US20070142435A1 (ru)
EP (1) EP1737848A1 (ru)
JP (1) JP2007530580A (ru)
KR (1) KR20060130682A (ru)
CN (1) CN1956978A (ru)
AR (1) AR048336A1 (ru)
AU (1) AU2005230934A1 (ru)
BR (1) BRPI0509245A (ru)
CA (1) CA2560649A1 (ru)
CR (1) CR8603A (ru)
DO (1) DOP2005000039A (ru)
EC (1) ECSP066878A (ru)
IL (1) IL178031A0 (ru)
MA (1) MA28547B1 (ru)
MX (1) MXPA06010610A (ru)
NO (1) NO20064811L (ru)
PA (1) PA8627601A1 (ru)
PE (1) PE20060084A1 (ru)
RU (1) RU2330034C1 (ru)
TN (1) TNSN06278A1 (ru)
TW (1) TW200602035A (ru)
UA (1) UA83738C2 (ru)
UY (1) UY28821A1 (ru)
WO (1) WO2005097780A1 (ru)
ZA (1) ZA200607752B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20071148A1 (es) * 2006-03-29 2007-12-10 Sanofi Aventis Mejoras en la preparacion de intermedios que conducen a hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona
AR065616A1 (es) * 2007-03-07 2009-06-17 Sanofi Aventis Sintesis regioselectiva de ullmann de acido 4- bromo-3- metil-5- propoxi- tiofeno-2- carboxilico
WO2008115912A1 (en) * 2007-03-21 2008-09-25 Sanofi-Aventis Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid
AR065859A1 (es) * 2007-03-29 2009-07-08 Sanofi Aventis Ester de 2,5-dioxo-pirrolidin-1-ilo de acido 4-bromo-3-metil-5-propoxitiofen-2- carboxilico ,su sintesis regioespecifica y un intermedio del mismo
AR065858A1 (es) * 2007-03-29 2009-07-08 Sanofi Aventis Metodo para preparar el inhibidor de triptasa [ 4-(5-aminoetil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona.
JP2011504499A (ja) * 2007-11-21 2011-02-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ トリプターゼ阻害剤として使用するためのスピロピペリジン
CA2713131C (en) 2008-01-24 2017-01-10 Soligenix, Inc. Topically active steroids for use in interstitial pulmonary fibrosis
RU2509766C2 (ru) * 2008-08-22 2014-03-20 Санофи-Авентис [4-(5-аминометил-2-фторфенил)-пиперидин-1-ил]-[7-фтор-1-(2-метоксиэтил)-4-трифторметокси-1н-индол-3-ил]-метанон как ингибитор триптазы тучных клеток
AR074776A1 (es) 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
FR2955324A1 (fr) * 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
CN102574792B (zh) * 2009-09-24 2014-07-09 赛诺菲-安万特美国有限责任公司 (4-氟-3-(哌啶-4-基)-苯甲基)-氨基甲酸叔丁酯的合成及其中间体
EP2515851A1 (en) * 2009-12-23 2012-10-31 Sanofi Treatment for inflammatory bowel disease
WO2011087652A1 (en) * 2009-12-23 2011-07-21 Sanofi Tropinone benzylamines as beta-tryptase inhibitors
CN102770425A (zh) * 2009-12-23 2012-11-07 赛诺菲 用作β-类胰蛋白酶抑制剂的吲哚基-哌啶基苄胺类化合物
AR080255A1 (es) * 2010-02-24 2012-03-21 Sanofi Aventis Tratamiento de afecciones alergicas dermatologicas. composicion farmaceutica
GEP201706608B (en) 2011-10-07 2017-01-25 Takeda Pharmaceuticals Co 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases
MX2019009485A (es) * 2017-02-10 2019-11-05 Genentech Inc Anticuerpos contra triptasa, composiciones de estos y usos de estos.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012362D0 (en) * 2000-05-22 2000-07-12 Aventis Pharma Ltd Chemical compounds
PL360495A1 (en) * 2000-05-22 2004-09-06 Aventis Pharmaceuticals Inc. Arylmethylamine derivatives for use as tryptase inhibitors

Also Published As

Publication number Publication date
JP2007530580A (ja) 2007-11-01
MA28547B1 (fr) 2007-04-03
CN1956978A (zh) 2007-05-02
BRPI0509245A (pt) 2007-09-11
NO20064811L (no) 2006-10-23
UY28821A1 (es) 2005-10-31
TNSN06278A1 (en) 2007-12-03
PE20060084A1 (es) 2006-03-09
WO2005097780A1 (en) 2005-10-20
AU2005230934A1 (en) 2005-10-20
IL178031A0 (en) 2006-12-31
RU2330034C1 (ru) 2008-07-27
EP1737848A1 (en) 2007-01-03
KR20060130682A (ko) 2006-12-19
ZA200607752B (en) 2008-05-28
TW200602035A (en) 2006-01-16
AR048336A1 (es) 2006-04-19
RU2006137717A (ru) 2008-05-10
DOP2005000039A (es) 2005-10-31
CR8603A (es) 2007-06-08
PA8627601A1 (es) 2006-01-23
ECSP066878A (es) 2006-11-24
US20070142435A1 (en) 2007-06-21
CA2560649A1 (en) 2005-10-20
MXPA06010610A (es) 2006-12-15

Similar Documents

Publication Publication Date Title
UA83738C2 (en) [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase
MY141939A (en) Pyridazine derivatives and their use as therapeutic agents
WO2010022196A3 (en) [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626572A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626139A (en) Heterocyclic derivatives and their use as therapeutic agents
GB0112348D0 (en) Compounds
TW200624427A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626592A (en) Heterocyclic derivatives and their use as therapeutic agents
TNSN06032A1 (en) Pyridazine derivatives and their use as therapeutic agents
TW200626148A (en) Heterocyclic derivatives and their use as therapeutic agents
PL360495A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
UA89035C2 (ru) Эфиры гидроксамовых кислот и их фармацевтическое применение
MEP54608A (en) Arylmethylamine derivatives for use as tryptase inhibitors
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
DE60014916D1 (de) Die Verwendung eines Benzimidazoles zur Herstellung eines Medikamentes zur Krebsvorbeugung
MX2007013624A (es) Inhibidores de proteina cinasa.
SE0102440D0 (sv) New compound
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
TW200606164A (en) New compounds
MY156278A (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
IL160082A0 (en) Quinoline derivatives and use thereof as antitumor agents
TNSN08093A1 (en) Quinoline derivatives and use as antitumor agents
MY144229A (en) Pyridazine derivatives and their use as therapeutic agents